Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix
NCT ID: NCT00430144
Last Updated: 2012-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
16 participants
INTERVENTIONAL
2007-01-31
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer
NCT05179317
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
NCT05715840
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
NCT05179239
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
NCT00548418
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
NCT00006224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* list item two, to evaluate duration of primary response for responding patients
* list item three, to evaluate time to disease progression
* list item four, to evaluate progression free survival and overall survival.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CKD-602
Belotecan(CKD-602)
Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belotecan(CKD-602)
Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* One of the following histologic types
* Squamous cell carcinoma
* Adenocarcinoma
* Adenosquamous carcinoma
* Clinically measurable disease
* Performance status of 0, 1, 2 on the ECOG criteria
Exclusion Criteria
* Patient previously treated with topoisomerase-I inhibitor
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sokbom Kang
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sokbom Kang
director, gynecologic oncology research branch
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sokbom Kang
Role: PRINCIPAL_INVESTIGATOR
National cancer cencer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National cancer center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hwang JH, Lim MC, Seo SS, Park SY, Kang S. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix. Jpn J Clin Oncol. 2011 May;41(5):624-9. doi: 10.1093/jjco/hyr017. Epub 2011 Feb 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCCCTS-06-214
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.